Cover ImageSALE
市場調查報告書

日本的再生醫療市場:2016∼2020年

Regenerative Medicine Market in Japan 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 373457
出版日期 內容資訊 英文 102 Pages
訂單完成後即時交付
價格
Back to Top
日本的再生醫療市場:2016∼2020年 Regenerative Medicine Market in Japan 2016-2020
出版日期: 2016年09月28日 內容資訊: 英文 102 Pages
簡介

再生醫療使用的3個主要技術,是小分子與生物製品,基因治療,及細胞治療。小分子及生技藥品有助於有疾病的細胞和組織的再生,細胞治療是治療現有的細胞的功能。日本的再生醫療市場,預計2016∼2020年以35.3%的年複合成長率擴大。

本報告提供日本的再生醫療市場相關調查,市場現狀及成長預測,市場規模,各產品,各用途市場區隔,及主要供應商簡介等彙整資料。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 日本的醫療改革

第6章 日本的法律制度

  • ASRM
  • PMD法

第7章 償付方案

第8章 基因治療:再生醫療新的領域

第9章 產品研發線

第10章 市場情況

  • 市場概要
  • 波特的五力分析

第11章 各產品市場區隔

  • 細胞治療
  • 組織鷹架

第12章 各用途市場市場區隔

  • 皮膚科
  • 肌肉骨骼
  • 心血管
  • 其他

第13章 推動市場的要素

  • 法律制度的變化促進再生醫療迅速的認證
  • 日本國內供應商和跨國公司的合作增加
  • 近幾年的產品認證加速市場成長
  • 政府的配合措施牽引日本的再生醫療市場

第14章 促進要素的影響

第15章 市場課題

  • 關乎再生醫療倫理的課題
  • 臨床實驗的成本和失敗率高與不合適的臨床證據
  • 日本的再生醫療市場與其他已開發國家比較的競爭力低

第16章 促進要素與課題的影響

第17章 市場趨勢

第18章 供應商環境

  • 競爭模式
  • 主要消息
  • 產品認證
  • 聯盟
  • 收購合併
  • 其他

第19章 主要供應商分析

  • CellSeed
  • JCR製藥株式會社
  • Japanese Tissue Engineering Co (J-TEC)
  • Terumo Corporation
  • 今後活躍的供應商
  • 其他值得注意的供應商

第20章 附錄

第21章 關於Technavio

目錄
Product Code: IRTNTR10337

About Regenerative Medicine

Regenerative medicine deals with the process of using therapeutically induced or laboratory-grown human tissue to treat damaged or diseased human cells, tissues, or organs. It focuses on repairing, replacing, or regenerating damaged cells, and thus offers a paradigm shift in healthcare treatment. The three main technologies used in regenerative medicine are small molecules and biologics, gene therapy, and cell therapy. Small molecules and biologics help in the regeneration of diseased cells and tissues, whereas cell therapy helps in treating the functioning of existing cells.

Technavio's analysts forecast the regenerative medicine market in Japan to grow at a CAGR of 35.3% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the regenerative medicine market in Japan for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of various types of regenerative medicine products to end-users like hospitals, ambulatory surgical centers (ASCs), and clinical research laboratories.

The market is divided into the following segments based on product:

  • Tissue Scaffold
  • Cell Therapy

Technavio's report, Regenerative Medicine Market in Japan 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • CellSeed
  • JCR Pharmaceuticals
  • Japan Tissue Engineering
  • Terumo
  • Astellas
  • Caladrius Biosciences
  • Healios
  • Fujifilm
  • Rohto Pharmaceuticals

Other Prominent Vendors

  • FUJISOFT Tissue Engineering
  • MediBIC
  • MEDI NET
  • Nikon
  • TAKARA
  • CMIC
  • EPS
  • Cyfuse Biomedical
  • Irvine Scientific
  • Kaken
  • Regience
  • Sumitomo Dainippon
  • Takeda
  • Alfresa
  • MEDIPAL Holdings
  • TOHO

Market driver

  • Growing partnerships of MNCs with local vendors in Japan
  • For a full, detailed list, view our report

Market challenge

  • High cost and failure rate in clinical trials coupled with inadequate clinical evidence
  • For a full, detailed list, view our report

Market trend

  • Strong pipeline portfolio of regenerative medicines
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Healthcare reforms in Japan

PART 06: Regulatory landscape in Japan

  • ASRM
  • PMD Act

PART 07: Reimbursement scenario

  • Reimbursement scenario for regenerative medicine in Japan

PART 08: Gene therapy: An emerging field in regenerative medicine

PART 09: Pipeline portfolio

PART 10: Market landscape

  • Market overview
  • Five forces analysis

PART 11: Market segmentation by product

  • Cell therapy
  • Cell therapy regenerative medicine market in Japan
  • Tissue scaffold
  • Tissue scaffold regenerative medicine market in Japan

PART 12: Market segmentation by application

  • Dermatology
  • Musculoskeletal
  • Cardiovascular
  • Other

PART 13: Market drivers

  • Transformation of regulatory landscape fostering quick approval of regenerative medicines
  • Growing partnerships of MNCs with local vendors in Japan
  • Recent product approvals fuel the market growth
  • Government initiatives driving regenerative medicine market in Japan

PART 14: Impact of drivers

PART 15: Market challenges

  • Ethical challenges involved in regenerative medicine
  • High cost and failure rate in clinical trials coupled with inadequate clinical evidence
  • Low competitive edge of Japanese regenerative medicine market over other developed nations

PART 16: Impact of drivers and challenges

PART 17: Market trends

  • Strong pipeline portfolio of regenerative medicines
  • Entry of new players expanding the applications of regenerative medicine
  • Strategic collaborations and acquisitions
  • Advent of 3D tissue bioprinters for the development of regenerative medicines

PART 18: Vendor landscape

  • Competitive scenario
  • Key news
  • Product approvals
  • Partnerships
  • Mergers and acquisitions
  • Other

PART 19: Key vendor analysis

  • CellSeed
  • JCR Pharmaceuticals
  • Japan Tissue Engineering (J-TEC)
  • Terumo
  • Upcoming vendors
  • Other prominent vendors

PART 20: Appendix

  • List of abbreviations

PART 21: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Regenerative medicine application in various therapeutics
  • Exhibit 03: Major applications of regenerative medicine in Japan
  • Exhibit 04: Regenerative medicine legislation acts in Japan
  • Exhibit 05: Product approval and regulatory characteristics in Japan
  • Exhibit 06: Overview of regenerative medicine regulation acts
  • Exhibit 07: Landscape of regenerative medicine in Japan
  • Exhibit 08: Risk categories of regenerative medical technologies
  • Exhibit 09: Regenerative medicine approval process in Japan under the ASRM
  • Exhibit 10: Regenerative medicine approval process in Japan under PMD Act
  • Exhibit 11: Comparison of traditional and new product approval process under the PMD Act
  • Exhibit 12: Conditional approvals for regenerative medical products versus regular approval for pharmaceuticals
  • Exhibit 13: Japan's NHI pricing methods
  • Exhibit 14: NHI pricing calculation for TEMCELL HS
  • Exhibit 15: NHI pricing calculation for HeartSheet A kit
  • Exhibit 16: NHI pricing calculation for HeartSheet B kit
  • Exhibit 17: Gene therapy research by sponsorship
  • Exhibit 18: Regenerative medicine pipeline products in Japan
  • Exhibit 19: Pipeline analysis of regenerative medicine in Japan 2015
  • Exhibit 20: Pipeline products of regenerative medicine for cell therapy in 2015
  • Exhibit 21: Key developments in regenerative medicine market in Japan 2015
  • Exhibit 22: Regenerative medicine market in Japan 2015-2020 ($ millions)
  • Exhibit 23: Regenerative medicine market in Japan: Optimistic and pessimistic analyses 2015-2020
  • Exhibit 24: Optimistic and pessimistic market analysis of regenerative medicine in Japan 2015-2020
  • Exhibit 25: Five forces analysis
  • Exhibit 26: Regenerative medicine market in Japan by product 2015 and 2020
  • Exhibit 27: Positioning of segments (by product type) in regenerative medicine market in Japan 2015
  • Exhibit 28: Regenerative medicine market in Japan: Lifecycle analysis by product 2015
  • Exhibit 29: Cell therapy overview
  • Exhibit 30: Ethical issues involved in different cell therapy research category
  • Exhibit 31: Stem cell research policies in Japan
  • Exhibit 32: Key cell therapy products marketed in Japan
  • Exhibit 33: Cell therapy regenerative medicine market in Japan 2015-2020 ($ millions)
  • Exhibit 34: Opportunity analysis of cell therapy regenerative medicine market in Japan
  • Exhibit 35: Collaborations for R&D of tissue scaffold
  • Exhibit 36: Tissue scaffold regenerative medicine market in Japan 2015-2020 ($ millions)
  • Exhibit 37: Opportunity analysis of tissue scaffold in Japan regenerative medicine market
  • Exhibit 38: Regenerative medicine market in Japan by product type 2015-2020 ($ millions)
  • Exhibit 39: Regenerative medicine market in Japan 2015-2020 (%)
  • Exhibit 40: Overview of the regenerative medicine dermatology market in Japan
  • Exhibit 41: Pipeline of regenerative medicine for dermatology
  • Exhibit 42: Overview of musculoskeletal regenerative medicine market in Japan
  • Exhibit 43: Overview of cardiovascular regenerative medicine market in Japan
  • Exhibit 44: Regulatory guidelines in Japan
  • Exhibit 45: Approval process of SAKIGAKE assignment system
  • Exhibit 46: Partnerships of MNCs with local vendors in Japan
  • Exhibit 47: MHLW budget on drug discovery using iPS cells ($ millions)
  • Exhibit 48: Impact of drivers
  • Exhibit 49: Force field analysis of regenerative medicine market in Japan
  • Exhibit 50: Impact of drivers and challenges
  • Exhibit 51: Regenerative medicine pipeline portfolio 2015
  • Exhibit 52: Current applications of regenerative medicine
  • Exhibit 53: Future applications of regenerative medicine
  • Exhibit 54: Major strategic collaborations and acquisitions in Japan
  • Exhibit 55: Impact of trends in regenerative medicine in Japan 2015-2020
  • Exhibit 56: Presence of vendors in regenerative medicine
  • Exhibit 57: CellSeed: Profile
  • Exhibit 58: CellSeed: Strength analysis
  • Exhibit 59: CellSeed: Growth strategy matrix
  • Exhibit 60: CellSeed: Opportunity assessment
  • Exhibit 61: JCR Pharmaceuticals: Profile
  • Exhibit 62: JCR Pharmaceuticals: Strength analysis
  • Exhibit 63: JCR Pharmaceuticals: Growth strategy matrix
  • Exhibit 64: JCR Pharmaceuticals: Opportunity assessment
  • Exhibit 65: J-TEC: Profile
  • Exhibit 66: J-TEC: Strength analysis
  • Exhibit 67: J-TEC: Growth strategy matrix
  • Exhibit 68: J-TEC: Opportunity assessment
  • Exhibit 69: Terumo: Profile
  • Exhibit 70: Terumo: Strength analysis
  • Exhibit 71: Terumo: Growth strategy matrix
  • Exhibit 72: Terumo: Opportunity assessment
Back to Top